Those take years, years we don’t have. What we do have is increasing reproducibility in dozens of hospitals across the globe, and the sum sample size is now in the hundreds if not thousands. If you don’t find that encouraging given the uniquely fast timeline of this pandemic, then nothing will be interesting to you.

Perhaps you don’t find it encouraging, but the doctors at UPenn Medical sure did. I’m curious what your credentials are to qualify you downplaying their findings down to nothing but a “fascinating” satisfaction of intellectual curiosity, I’m sure they would appreciate you telling them to their faces it wasn’t worth the effort. Some of us, however, do appreciate due diligence.

I’ll be the first to admit in vitro assays rarely translate to efficacy in human. But given that the evidence for hydroxychloroquine, an already FDA approved drug for malaria, is increasing in support of the hypothesis that it improves the recovery time for Covid19, any researcher should be able to appreciate the additional validation via verifying the biochemical mechanism, even if it is in a Petri dish. After all, you typically need some of that data to justify moving forward with human clinical trials in the first place.